Increased Urine IgM and IgG2 Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes
Table 4
Diabetic patients with micro- or macroalbuminuria: effects of treatment on urinary indices.
Dalteparin
Placebo
Baseline
At end point
Baseline
At end point
U-Albumin (mg/mmol)
8.5 (0.9–435)
11.3 (1.5–311)
23.2 (2.1–187)
7.9 (0.9–273) ()
U-IgG2 (mg/mmol)
0.46 (0–20.7)
0.83 (0.13–35.1)
2.99 (0.02–99.4)
2.60 (0–70.0)
U-IgG4 (mg/mmol)
0.21 (0–3.94)
1.02 (0.04–7.16)
0.50 (0.03–28.7)
0.15 (0–53.7) ()
U-IgG2/u-IgG4
1.88 (1–10.5)
3.05 (0.33–9.16)
5.57 (0.8–9.7)
4.47 (0.35–24.1)
U-GAG (mg/mmol)
2.31 (0–4.52)
3.97 (1.25–6.1)*##
2.70 (0–11.1)
2.49 (0–5.19) ()
U-IgM (mg/mmol)
0.03 (0–0.05)
0.03 (0.01–0.12)
0.03 (0–0.13)
0.02 (0–0.14)
TGF-β1 (mg/mmol)
4.44 (1.4–15.9)
4.09 (2.14–14.12)
4.5 (1.8–16.5)
3.5 (1.19–22.44) ()
GFR (mL/min)
74 (36–140) ()
76 (18–208) ()
71 (38–107) ()
67 (34–113) ()
IGFBP-1 (μg/L)
66 (8–313)
105 (23–219)* ()
60 (20–130)
46 (10–161)
Data are given as the median (with minimum and maximum values in parentheses) of the ratio between urinary concentrations of substance and u-creatinine. * versus placebo; ## versus baseline. GFR: glomerular filtration rate: creatinine clearance.
